Kala Bio, Inc. (NASDAQ:KALA) Financings

Kala Bio, Inc.

Financings

RaiseDate
Registered direct offering of common stock (or pre-funded warrants in lieu thereof)
Closed: US$10M raised · US$1 a share · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Repay certain indebtedness and general corporate purposes
Dec 5, 2025
Private placement of non-voting convertible preferred stock
Tranche closed: US$1.8M raised
Buyers: David E. Lazar ($6 million of non-voting convertible preferred stock; $1.8 million of Series AA preferred in first closing, $4.2 million of Series AAA preferred in second closing)
Insiders: Investor David E. Lazar was appointed Chief Executive Officer and Chairman of the Board effective immediately.
Use of proceeds: Evaluation and redevelopment of product candidates and patent portfolio, working capital and funding for a potential strategic transaction
Dec 1, 2025
Private placement of common stock and Series I Convertible Non-Redeemable Preferred Stock
Announced: about US$10.75M · US$6.44 a share
Buyers: SR One; Cormorant Asset Management; Woodline Partners
Use of proceeds: Advance clinical development of KPI-012 for persistent corneal epithelial defect and general corporate purposes
Dec 30, 2024

Read by 6ix AI from the company's releases